/, BRAF, BRAF L597S mutant melanoma, BRAF Mutant Melanomas, BRAF V600E/K, BRAF V600E/K mutant melanoma, BRAF mutant, BRAF mutant melanoma, BRAF mutant tumors, BRAFi, Cell lines, Class II, Class II BRAF Mutant Melanomas, K, L597S, LY3009120, MAPK, MAPKi, MEK, PDX, PDXs, V600, V600 BRAF mutant tumors, V600E, V600E/, binimetinib, class, class I and II BRAF mutant, class II BRAF mutant cells, class II BRAF mutant melanoma, cobimetinib, dMAPKi, dabrafenib, encorafenib, melanoma, melanoma brain metastases, melanoma cell lines, metastatic melanoma, mice, patient, patients, trametinib, vemurafenib